Clinical Trial Update: A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study of dalotuzumab (MK-0646) in subjects with advanced solid tumors has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Dalotuzumab (dalotuzumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2018-10-09